Nexalin Technology (NXL) Invested Capital (2021)

Nexalin Technology's (NXL) quarterly Invested Capital came in at $37200.0 in Q4 2021.

Nexalin Technology (NXL) Invested Capital (2021) Analysis & Trends

Nexalin Technology's Invested Capital history runs 1 years deep, the most recent figure standing at $37200.0 for Q4 2021.

  • On a quarterly basis, Invested Capital changed N/A year-over-year to $37200.0 in Q4 2021; TTM through Sep 2022 was $37200.0, a N/A change from a year earlier, with the FY2021 full-year figure at $37200.0, changed N/A from the prior year.
  • Invested Capital steadied at $37200.0 in Q4 2021 per NXL's latest filing.
  • Across five years, Invested Capital topped out at $37200.0 in Q4 2021 and bottomed at $37200.0 in Q4 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Invested Cap. (Qtr)
1 Abbott Laboratories 201.40 Bn 194.75 Bn 6.27 Bn 4.41 Bn
2 Stryker 122.29 Bn 119.41 Bn 3.81 Bn 499.00 Mn
3 Medtronic 105.01 Bn 96.40 Bn 6.41 Bn 1.79 Bn
4 Boston Scientific 64.81 Bn 63.59 Bn 3.61 Bn 41.00 Mn
5 Edwards Lifesciences 55.28 Bn 51.60 Bn 1.29 Bn -
6 Dexcom 29.06 Bn 27.94 Bn 750.30 Mn -
7 Koninklijke Philips 29.02 Bn 25.93 Bn 2.07 Bn 1.41 Bn
8 GE HealthCare Technologies 28.27 Bn 26.20 Bn 1.98 Bn 7.00 Mn
9 Smith & Nephew 25.80 Bn 25.22 Bn - 15.00 Mn
10 Nexalin Technology 9.32 Mn 6.61 Mn 13,133.00 -

Historic Data

Download Data
DateValue
Dec 31, 2021 37,200.00